| Literature DB >> 25805592 |
Neha Mehta-Shah1, Anas Younes2.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma. Next-generation sequencing techniques have improved our understanding of the molecular pathways that may drive oncogenesis. Many novel classes of drugs are in development that may improve the treatment of DLBCL, either as single agents or in combination, that exploit their synergy to overcome resistance. We review the key novel targets and therapeutics in the treatment of DLBCL, including immunomodulatory agents and immunotherapy.Entities:
Mesh：
Substances：
Year: 2015 PMID： 25805592 DOI： 10.1053/j.seminhematol.2015.01.007
Source DB: PubMed Journal: Semin Hematol ISSN： 0037-1963 Impact factor: 3.851